Toxicity-over-time analysis of anti-EGFR-based maintenance versus stop&go in left-sided, RAS/BRAF wild-type metastatic colorectal cancer
Clicks: 3
ID: 314941
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
0.6
/100
3 views
2 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #80 of 332 articles by views in JNCI Journal of the National Cancer Institute
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 332 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
BACKGROUND: Doublet chemotherapy plus anti-EGFR is a standard of care in left-sided, microsatellite stable, RAS/BRAF wt (wt) mCRC. Guidelines recommend treatment de-escalation after achieving disease control with induction. Maintenance and intermittent (stop&go) strategies were investigated but not directly compared. METHODS: We performed an individual patient data pooled analysis of three randomized phase II trials (PanaMa, Valentino, PRODIGE-28 TIME), focused on toxicity analysis. Only patients with left-sided, non-MSI-H, RAS/BRAF V600E wt who started protocol-planned post-induction were included and stratified into three treatment groups: 5-FU/LV plus anti-EGFR maintenance, anti-EGFR alone, stop&go. Longitudinal toxicity data were collected and analyzed according to literature-based approach (Toxicity over Time; ToxT), incorporating dimension of time into adverse event (AE) assessment and analyzing individual and groups of AEs comparing treatment groups. RESULTS: Overall, 327 patients were included: 166, 109 and 52 patients received anti-EGFR plus 5-FU/LV maintenance, anti-EGFR alone and stop&go, respectively. Mean AE grades for chemotherapy-related toxicity showed different longitudinal patterns. Mean Grades in stop&go were lower in early cycles and increased later, higher values were reported for combination maintenance. Considering anti-EGFR-related skin toxicity, the mean AE grade was constantly lower for stop&go compared to maintenance groups. Overall, grade 3/4 AEs were more represented in maintenance groups versus stop&go, although the predominant grade was 1 across cycles for all groups. CONCLUSIONS: In our IPD analysis, indirectly comparing three clinical trials, stop&go showed lower anti-EGFR skin-related toxicity versus maintenance. Shared decision-making, considering patient and tumor features and treatment tolerability, may allow defining optimal de-intensification strategy.
| Reference Key |
openalex_W7162326477
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Alessandra Raimondi, Gabriele Tinè, Valerie Boige, Alexej Ballhausen, Sophie Gourgou, Arndt Stahler, Giovanni Randon, Paolo Manca, Emilie Brument, Annabel Helga Sophie Alig, F Morano, Michele Prisciandaro, Margherita Ambrosini, Roberta Fazio, Yiyi Zhu, Rosalba Miceli, Olivier Bouche, Dominik Paul Modest, Filippo Pietrantonio |
| Journal | JNCI Journal of the National Cancer Institute |
| Year | 2026 |
| DOI |
10.1093/jnci/djag160
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.